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Aims: To determine whether lower postprandial glucose (PPG) levels after intake of a
diabetes-specific formula (DSF) compared with a standard formula were maintained after
4 weeks use.
Methods: Randomized, controlled, double-blind, parallel-group study. Forty-four type 2 dia-
betes patients on oral anti-diabetes medication consumed 2  200 mL/day of a DSF (Diasip1)
or an isocaloric standard, fiber-containing formula for 4 weeks. PPG responses were assessed
at baseline and after 4 weeks by iAUC and (delta) peak glucose concentrations.
Results: PPG response was significantly lower in the DSF group after first intake and
remained significantly lower after 4 weeks use. Postprandial insulin, fasting glucose, insulin
resistance, fructosamine and lipid levels did not differ between groups after 4 weeks. Within
the standard group, fasting glucose and HOMAIR significantly increased over the interven-
tion period. Changes in body weight between groups were significantly different, with an
increase in the standard group. Both products were equally well tolerated.
Conclusions: Superior PPG control by DSF was maintained after 4 weeks use, showing that
this formula has added value with respect to PPG control for type 2 diabetes patients
compared to a standard, fiber-containing formula. The observed effects on body weight,
fasting glucose and HOMAIR may further support the use of a DSF.
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Postprandial hyperglycemia significantly contributes to over-
all glycemic control in type 2 diabetes patients [1,2]. Further-
more, epidemiological studies have shown a strong and
independent relationship between postprandial blood glucose
excursions and cardiovascular co-morbidities in type 2* Corresponding author at: Nutricia Advanced Medical Nutrition, Danon
Wageningen, The Netherlands. Tel.: +31 (0)317 467 814; fax: +31 (0)31
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Abbreviations: ANOVA, analysis of variance; BMI, body mass inde
hemoglobin; HDL, high density lipoprotein; HOMAIR, homeostasis mod
the curve; ITT, intention-to-treat; LDL, low density lipoprotein; SD, st
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  Open access under the Elsevier OA licensediabetes patients [3–5]. Hyperglycemia and fluctuating blood
glucose levels have been attributed directly to the develop-
ment of cardiovascular disease [6–8]. The International
Diabetes Federation has recently recognized, in specific
guidelines, the significance and harmful effects of postpran-
dial hyperglycemia and the need to measure and treat it [9].
Diets with a low glycemic load are recommended in control-
ling postprandial plasma glucose levels [10,11].e Research, Centre for Specialised Nutrition, PO Box 7005, 6700 CA
7 466 500.
x; En%, energy percent; GI, glycemic index; HbA1c, glycosylated
el assessment for insulin resistance; iAUC, incremental area under
andard deviation; SE, standard error.
.
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oral formulas have been developed, which aim to result in
lower (postprandial) glucose levels than standard formulas.
Traditionally, these formulas contained less carbohydrate (35–
40 energy percent (En%)) and typically more fat (40–50 En%),
with a large contribution from monounsaturated fatty acids,
typically more than 60% of total fat content [12]. However,
nutritional guidelines for diabetes patients published by the
Diabetes Nutrition Study Group of the European Association
for the Study of Diabetes recommend that the fat content of a
diet should not exceed 35 En%, and carbohydrate intake
should range between 45 and 60 En% [13].
Recently, a diabetes-specific formula containing less than
35% of fat (34 En%) and more than 45 En% carbohydrate (47 En%)
was developed. The diabetes-specific formula contains several
low (GI) and/or slowly digestible carbohydrates, like isomaltu-
lose lactose and slowly digestible starch [14–17] (starch which is
slowly digested and therefore, intake of this type of starch leads
to a smaller rise in postmeal glucose levels compared to
‘‘normal’’ starch, which is quickly digested [17]), whereas the
major carbohydrate in the standard formula is the high-GI
maltodextrin. These specific carbohydrates were combined
with specific proteins (soy and whey) and fibers in order to keep
the postprandial glucose response as low as possible. Single
bolus or day-long consumption of this formula resulted in lower
postprandial glucose levels than a standard, fiber-enriched
nutritional formula in type 2 diabetic patients [18,19]. However,
no data are available on the effects of this formula on
postprandial glucose levels after longer term use and whether
adaptation by the body occurs after longer term use. There are
for instance no experimental data available on the effect of
longer term use of isomaltulose on the enzyme kinetics or
expression levels of the responsible isomaltulose degrading
enzymes. Isomaltulose is one of the major components in the
formula providing the lower postmeal glucose levels. In theory,
the enzyme kinetics of isomaltulose may be adapted after
longer term exposure of the body to isomaltulose, resulting in a
more rapid digestion and thereby higher postmeal glucose
response. Therefore, in the present study, the effect of the
diabetes-specific formula on postprandial glucose levels was
studied after 4 weeks consumption by type 2 diabetes patients.
Furthermore, the effects of 4 weeks consumption on other
glycemic and lipid parameters, weight and tolerance were
studied. The formula was used as a breakfast and afternoon or
evening snack replacer in type 2 diabetes patients. Since it is
sometimes thought that diabetes patients can use standard
formulas as long as these contain fibers, an isocaloric, liquid,
fiber-containing standard formula was used for comparison.
2. Materials and methods
The study was a randomized, controlled, double-blind,
parallel-group study, performed at one study center in the
Netherlands (Julius Center, Utrecht, The Netherlands).
2.1. Subjects
In total, 44 ambulatory type 2 diabetes patients (25 male, 19
female) were included in this study.Inclusion criteria were diagnosis of type 2 diabetes according
to WHO criteria for more than 6 months, male with an age >18
years or postmenopausal female, HbA1c between 6.5% and
8.0%, body mass index (BMI) between 18 and 35 kg/m2, and
stable treatment with metformin and/or sulfonylureas for at
least 2 months and expected to remain stable throughout the
duration of the study. If lipid-lowering drugs were used, their
use was to be stable and controlled for at least 2 months and
expected to remain stable throughout the duration of the study.
Exclusion criteria were a weight-loss diet, any gastrointes-
tinal disease that interferes with bowel function and nutri-
tional intake, significant heart (NYHA class IV), hepatic
(transaminase greater than 3 times upper limit of normal),
or renal disease (requiring dialysis or creatinine > 160 mmol/L),
infection requiring antibiotics within 3 weeks prior to study
entry, concomitant therapy with insulin or anti-diabetic
medication other than metformin and sulfonylureas, therapy
with systemic glucocorticoids at or within 2 weeks prior to
study entry, alcohol abuse, fever and participation in other
intervention studies within 4 weeks of screening. Subjects
with galactosemia or lactose intolerance, and subjects
requiring a fiber-free diet, were also excluded.
The Independent Review Board Nijmegen (The
Netherlands) approved the study protocol. All subjects were
informed about the nature of the study and gave written
informed consent prior to study screening. The study was
performed in accordance with the principles relating to the
Declaration of Helsinki and GCP.
2.2. Treatments
Subjects were randomly allocated to receive either the
diabetes-specific formula or an isocaloric standard formula
according to a computer-generated randomization list using
two different randomization codes per treatment.
The subjects in the diabetes-specific formula group con-
sumed Diasip1 (Nutricia N.V., Zoetermeer, The Netherlands), a
flavored, 1 kcal/mL, diabetes-specific nutritional supplement
(47 En% carbohydrates, 19 En% protein, 34 En% fat (20 En%
monounsaturated fatty acids) and 2 g fibers/100 mL). The
control group received a flavored isocaloric, fiber-containing
standard formula (50 En% carbohydrates, 16 En% protein,
34 En% fat (20 En% monounsaturated fatty acids) and 1.5 g
fibers/100 mL). Both formulas contained the same amount and
quality of fat. Both formulas contained vitamins, minerals, and
trace elements in accordance with the regulations for Food for
Special Medical Purposes (1999/21/EC). Subjects consumed two
200 mL portions per day of either of the products for 4 weeks,
one as a replacement for breakfast and one as an in-between
snack in the afternoon or evening. Table 1 shows the
characteristics of the formula compositions.
2.3. Study design
After screening, the subjects visited the research center at the
beginning (visit 1, day 1) and at the end (visit 2, day 29) of the 4-
week period. Subjects had to refrain from alcohol consumption
and intense physical activities for, respectively, 24 and 48 h
before both visits and had to eat a standard meal (450 g,
125 kcal/100 g, 57 En% carbohydrates, 13 En% protein, and
Table 1 – Macronutrient composition of the formulas per 100 mL product (=100 kcal).
Ingredient Unit Diabetes-specific
formula
Standard
formula
Energy kcal 100 100
Protein g/En% 4.86/19 4.02/16
Whey protein 2.41 –
Soy protein 2.44 –
Casein – 3.95
Other (from raw materials) 0.01 0.07
Carbohydrate g/En% 11.63/47 12.55/50
Lactose 3.6 –
Isomaltulose 4.4 –
Glucose 0.3 –
Polysaccharides 3.1 12.2
Other (from raw materials) 0.3 0.35
Fat g/En% 3.78/34 3.78/34
Fiber 2.0 1.5
–: product does not contain the ingredient.
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center in the morning after an overnight fast (10 h) and body
temperature and weight were measured. Venous blood was
collected via a canula which was placed at least 30 min before
the first blood sample was taken. Subjects took their anti-
diabetes medication with 150 mL water 20 min before intake of
the study product. Subjects consumed either the diabetes-
specific formula or the standard formula (200 mL) and had to
finish it within 5 min. To determine the postprandial glucose
and insulin responses, venous blood samples were drawn 5 min
prior to product intake (basal sample) and 15, 30, 45, 60, 75, 90,
120, 150, 180, 210 and 240 min after intake. The sample taken
5 min prior to product intake was used to determine fasting
glucose levels. Besides postprandial measurements, also fast-
ing blood samples were collected at visits 1 and 2 for the
measurement of total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and
triglycerides, and for alanine aminotransferase, aspartate
aminotransferase, gamma glutamyltransferase, alkaline phos-
phatase, and creatinine and serum fructosamine levels. During
the assessment period subjects had to sit quietly.
During the 4-week study period, subjects filled out a diary
daily on actual formula consumption. Subjects had to record
volume and time of study product intake. On the 4 days
immediately preceding visit 1, on days 1–4, on days 15–18 and on
days 25–28, a gastrointestinal tolerance questionnaire was
completed by the subjects, reporting the intensity for the
symptoms ‘dry mouth’, ‘thirst’, ‘belching’, ‘heartburn’, ‘bloat-
ing’, ‘stomach pain’, ‘stomach cramps’, ‘abdominal pain’,
‘flatulence’, and ‘nausea’ on a 4-point scale ranging from ‘not
at all’ to ‘very much’. Furthermore, subjects recorded defecation
frequency and consistency on a 5-point scale. Any clinical study
event that was judged as an adverse event, either spontane-
ously reported by the subject or observed by the investigator,
was recorded in the study database and the investigator
documented the relationship with the study product.
2.4. Laboratory methods
All blood samples were centrifuged immediately (1000  g,
10 min, 4 8C), except for serum, which was allowed to clot atroom temperature (30 min) first. After centrifugation, plasma
and serum aliquots were stored at -20 8C until analysis. For the
analysis of HbA1c, EDTA whole blood was collected and stored
at 4 8C until analysis on the same day.
Plasma glucose and triglycerides were analyzed enzymati-
cally on a DxC (Beckman Coulter, Brea, CA, USA). Serum
insulin was measured using a chemiluminescence immuno-
assay (E170, Roche Diagnostics, Basel, Switzerland) and serum
fructosamine was measured using a colorimetric assay (Pentra
400, Horiba ABX Inc., Irvine, CA, USA). Plasma total cholesterol
and HDL cholesterol were determined on a DxC (Beckman
Coulter) using enzymatic colorimetric kits. LDL cholesterol
was estimated using the Friedewald equation [20].
Biochemical parameters and HbA1c were measured using
standardized HPLC methods (HA-8160, Menarini, Valkens-
waard, The Netherlands).
2.5. Outcome measures
The primary outcome measure was the 4 h postprandial
plasma glucose response, as assessed by the incremental area
under the curve (iAUC). As secondary outcome measures,
fasting glucose and insulin, postprandial peak glucose and
insulin, maximum postprandial glucose and insulin increase
from baseline (delta peak), postprandial glucose and insulin
levels per protocol time, 4 h postprandial insulin response
(iAUC), and gastrointestinal tolerance were defined. Other
parameters included product compliance, body weight, fast-
ing fructosamine, fasting plasma lipid profile and insulin
resistance assessed by HOMAIR.
2.6. Sample size
Calculation was performed for the parameter postprandial
glucose response, as assessed with iAUC0-4 h. Based on
results of a previously performed study [18] with a comparable
diabetes-specific product and a standard product containing
5 En% more carbohydrates, it was assumed that the mean
difference between groups was 40% (210 units). Based on this
and another previously performed study [21] it is assumed that
the common within-group standard deviation is 226. Applying
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of 80% to detect a difference of 210, a sample size of 20 for each
of the two groups was assumed to detect a statistically
significant difference between the groups. Assuming a
dropout rate of 10%, 22 subjects were needed per group to
detect a statistically significant difference.
2.7. Statistical analyses
All the data presented are from the intention-to-treat (ITT)
population.
Subject characteristics at screening and baseline were
evaluated using means (and SD) or median (and minimum and
maximum) for continuous parameters, and using percentages
and absolute numbers for dichotomous and categorical
parameters. BMI, duration of diabetes, HbA1c, fasting glucose
and the outcome measures were compared between the study
groups using ANOVA or the non-parametric Mann–Whitney
test, depending on the distribution of the data. Differences in
distribution of categorical data between study groups were
assessed by Fisher’s exact test.
The outcome measures were compared at visit 1, visit 2 and
for the change during the supplementation period (Dvisit
2  visit 1) between groups.
Within-group changes were analyzed using paired samples
t-test or the non-parametric paired Wilcoxon test, depending
on the distribution of the data. Possible confounding effects of
baseline BMI and fasting glucose concentrations at visit 1 were
tested for 4 h postprandial glucose response, postprandial
(delta) peak glucose concentration and HOMAIR at visit 1, visit
2 and the change during the supplementation period (Dvisit
2  visit 1).
All statistical analyses were performed using a two-sided
significance level of 5%, using SPSS version 15.0 for Windows,
Rel. 6 Sep. 2006, Chicago: SPSS Inc.Table 2 – Baseline characteristics of study population.
Diabetes-specific (n =
Age (years) 65.2  7.4 
Sex
Male (n (%)) 9 (41) 
Female (n (%)) 13 (59) 
Height (m) 1.69  0.09 
Weight (kg) 85.6  10.2 
BMI (kg/m2) 30.1  2.9 
Duration of diabetes (months) 84 (18–216) 
HbA1c (%) 6.9 (6.5–7.6) 
Class of anti-diabetic medication
Metformin (n (%)) 8 (36) 
Sulfonylureas (n (%)) 3 (14) 
Combination (n (%)) 11 (50) 
Statin use
No (n (%)) 6 (27) 
Yes (n (%)) 16 (73) 
Data are mean  SD or median (range) for continuous parameters, and n
–: not determined.
a p-value for differences between groups, ANOVA.
b p-value for differences between groups, Mann–Whitney.3. Results
Forty-four subjects were enrolled, 22 per treatment group, and
included in the ITT analyses. Forty-two subjects completed the
study. In the standard formula group, one subject dropped out
since he indicated that he would most likely forget to take the
study product twice a day. In the diabetes-specific formula
group, one subject dropped out due to difficulties in placing a
canula.
3.1. Subject characteristics and demographics
Baseline demographic data and subject characteristics are
shown in Table 2. Table 3 shows the metabolic characteristics
for all subjects at visit 1. Groups were comparable with regard
to all baseline characteristics.
3.2. Compliance
Subjects in the diabetes-specific formula and standard
formula group consumed on average 95.7  2.33 and
92.2  4.66% ( p = 0.79) of total daily intake (400 mL), respec-
tively.
3.3. Primary efficacy parameter
The 4 h postprandial glucose response (iAUC) was significantly
lower after consumption of the diabetes-specific formula
as compared with the standard formula group at visit 1
(129.8  26.0 and 264.8  26.6 mmol/L min, respectively;
p = 0.001) and remained significantly lower after the 4-week
intervention period (visit 2; 128.1  27.3 and 266.3  26.7;
p = 0.001). The change in iAUC over time was not different
between groups. 22) Standard (n = 22) p-value
64.2  5.9 –
16 (73) –
6 (27) –
1.73  0.08 –
84.8  12.3 –
28.3  3.3 0.06a
66 (10–504) 0.55b
6.9 (6.5–8.0) 0.56b
5 (23) –
4 (18)
13 (59)
2 (9) –
20 (91)
 (%) for categorical parameters.
Table 3 – Metabolic characteristics for all subjects randomized at visit 1.
Diabetes-specific
(n = 21)
Standard
(n = 22)
p-valuea
Glucose (mmol/L) 8.32  1.49 7.61  1.13 0.085
Triglycerides (mmol/L) 1.2 (0.6–2.9) 1.6 (0.5–3.2) 0.429
Total cholesterol (mmol/L) 4.2 (2.4–5.3) 3.9 (2.0–5.6) 0.503
HDL cholesterol (mmol/L) 1.08 (0.74–2.07) 1.04 (0.70–1.96) 0.444
LDL cholesterol (mmol/L) 2.3 (0.4–3.9) 2.0 (1.0–3.4) 0.318
Fructosamine (mmol/L) 252 (214–497) 278 (228–506) 0.259
Fasting insulin (mU/L) 9.0 (4.0–24.0) 8.0 (3.0–20.0) 0.407
Data are mean  SD or median (range).
a p-value for differences between groups was tested with Mann–Whitney for all parameters, except for fasting glucose, which was tested using
ANOVA.
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As shown in Fig. 1, from 60 until 90 min after consumption at
visit 1 and from 45 until 90 min at visit 2, the diabetes-specific
formula resulted in significantly lower plasma glucose con-
centrations compared with the standard formula. The maxi-
mum increase in postprandial plasma glucose levels above
baseline plasma glucose levels (delta peak) was also signifi-
cantly lower in the diabetes-specific formula group compared
with the standard formula group at both visits (1.8  0.2 vs.
3.6  0.3 mmol/L at visit 1 and 1.7  0.3 vs. 3.7  0.2 mmol/L at
visit 2, both p < 0.001). At visit 1 and visit 2, fasting plasma
glucose concentrations were not significantly different be-
tween groups ( p = 0.085 and p = 0.823, respectively). The change
in fasting glucose levels during the 4-week study period did
not differ significantly between groups ( p = 0.068), but fasting
glucose levels were significantly increased after 4 weeks in the
group consuming the standard formula (from 7.73  0.22 to
8.22  0.26 mmol/L; p = 0.011) and were not altered in the
diabetes-specific group (from 8.32  0.33 to 8.13  0.33 mmol/
L; p = 0.555).
The 4 h postprandial insulin response (iAUC) did not differ
significantly between the two groups after first intake (visit 1,
p = 0.058) nor after the 4-week intervention period (visit 2,
p = 0.181). No significant differences were observed between
the two groups in insulin levels over time in the 4 h
postprandial period (Fig. 2). Also no significant differences
were observed between the groups at either of the visits in the
(delta) postprandial peak insulin concentrations (data not
shown). Fasting serum insulin levels were comparable
between groups at the start of the study and also the change0 30 60 90 12 0 15 0 18 0 21 0 240
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Fig. 1 – Plasma glucose concentrations over time (mmol/L) at vis
SEs. *p < 0.05.during the 4-week study period was not different between
groups ( p = 0.206).
3.5. Other efficacy parameters
No differences between the groups at either visit were found in
the HOMAIR. The change in HOMAIR during the 4-week study
period was not significantly different between groups
( p = 0.078) but this change was significant after correction
for baseline BMI ( p = 0.037). Within the standard group
HOMAIR significantly increased from 2.84 (median) (range
0.91–7.91) to 3.38 (1.11–9.71) ( p = 0.013), whereas no significant
changes were observed within the diabetes-specific group:
3.52 (1.39–11.31) to 2.89 (1.32–11.33) ( p = 1.000).
Fasting levels of fructosamine, triglycerides and total, HDL
and LDL cholesterol were not significantly different between
groups at the start of the study, nor after 4 weeks. Also the
changes over time in any of these parameters were not
different between groups (data not shown).
Interestingly, the change in body weight was significantly
different between groups (0.3  0.2 kg in diabetes-specific
group and 0.6  0.2 kg in standard group; p = 0.006). The body
weight was not significantly different between groups at either
of the visits.
3.6. Tolerance and safety
Overall, both products were equally well tolerated, with a low
incidence and mild intensity of reported symptoms. For
instance, in the diabetes-specific group, for ‘abdominal pain’
15 study participants reported ‘not at all’, 4 reported ‘a little’, 20 30 60 90 120 150 18 0 210 24 0
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Fig. 2 – Serum insulin concentrations over time (mU/L) at visit 1 (A) and after 4 weeks (B). Data are means. Error bars are SEs.
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the standard group these numbers were 14, 6, 1, and 0,
respectively. Biochemical parameters of liver and kidney
function were comparable between groups at baseline and
week 4 and did not change over time, except for a clinically
non-relevant increase in median plasma gamma glutamyl-
transferase concentrations in the standard group ( p = 0.048).
There were no differences between the diabetes-specific
and standard formulas in the total number of product-related
(9 and 12, respectively) and non-related adverse events (9 and
17, respectively). There were equal numbers of subjects with
product-related adverse events (6 and 6, respectively). There
was no statistically significant difference between the groups
in the number of subjects with (12 in the diabetes-specific
group and 15 in the control) or without (10 and 7, respectively)
one or more adverse events. There were numerically fewer
reports of adverse events in the diabetes-specific group
compared to the standard group for diarrhea (2 and 8,
respectively) and flatulence (1 and 6, respectively). No serious
adverse event occurred during the study and no subjects
dropped out for product-related reasons.
4. Discussion
This study shows that ingestion of 200 mL of a diabetes-
specific formula resulted in significantly lower postprandial
glucose levels compared to a standard, fiber-containing
formula, both after a single bolus and after continuous
twice-daily use for 4 weeks. Postprandial insulin levels were
not different. Furthermore, consumption of the standard
formula increased fasting glucose levels and increased insulin
resistance, in contrast to the diabetes-specific formula, which
did not affect these parameters. The change in body weight
was also significantly different between groups, with an
increase in the standard and a decrease in the diabetes-
specific formula group. No differences in fructosamine,
insulin, or lipid levels were observed between groups after 4
weeks consumption. Both products were equally well tolerat-
ed, with a low incidence and mild intensity of reported
symptoms, and no clinically relevant differences were
observed in liver and kidney function.
The lower postprandial glucose response to the diabetes-
specific formula after 4 weeks indicates that no adaptation to
the diabetes-specific formula occurs after several weeks ofuse. Although the study period of 4 weeks is relatively short,
there are no reasons to assume that after longer term use
adaptation would occur. The lower postprandial glucose
response may be due to several properties and/or ingredients
of this formula, which are described in more detail elsewhere
[18,19]. In short, the major carbohydrate in the diabetes-
specific formula is isomaltulose a naturally occurring, low
glycemic index, slowly digestible carbohydrate. In vitro
studies using human small intestinal mucosa homogenate
as enzyme source, show that human intestinal enzymes are
able to hydrolyze isomaltulose, but the rates are slow
compared with sugars as maltose or sucrose [14,22]. This
slower hydrolyzation during gastrointestinal passages may be
responsible for the (s)lower rises in blood glucose and insulin
levels observed after isomaltulose intake as compared with
sucrose in both healthy and diabetic subjects [15,23]. In a
recent study using an ileostomy model, isomaltulose was
found to be essentially absorbed. Apparent digestibility of 50 g
of isomaltulose from two different meals was 95.5 and 98.8%.
Apparent absorption was 93.6 and 96.1%, respectively [24]. The
protein source is also different between the two formulas:
casein in the standard formula and a combination of whey and
soy protein in the diabetes-specific formula [25–28]. The
different types of fibers may have contributed to the difference
in postprandial glucose response as well. Finally, the slightly
different amount of carbohydrates, proteins and fibers may
also have played a role in the observed effect.
Surprisingly, it was found that replacement of breakfast
and one snack with a liquid, fiber-containing standard
formula, but not with a diabetes-specific formula, increased
fasting glucose levels and insulin resistance (HOMAIR). There
are a few other studies in which standard liquid meal
replacements were used by type 2 diabetes patients, i.e. full
meal replacement for 8 weeks providing 850 kcal/day [29] or
partial meal replacements achieving a daily caloric deficit of
500 kcal [30]. However, in these trials, the objective was to lose
weight and concomitantly with the observed weight loss (11%
[29] and 6% [30]), decreases in fasting glucose, HbA1c, and
lipids were found. The current trial was not designed to
actively lead to weight loss. The formulas were isocaloric.
However, the glycemic index of the diabetes-specific formula
was low, whereas the standard product had a medium GI.
Low-GI foods have consistently shown beneficial effects on
blood glucose control in both the short-term and the long-term
[31]. Since most low-GI foods are also rich in fiber, it is however
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fiber content to these health benefits. Only one study
determined the effect of two diets differing solely in their
GI, while containing the same amount of nutrients and dietary
fiber, on glycemic control in type 2 diabetes patients [32]. After
24 days on the low GI diet, insulin sensitivity was improved
and fasting glucose levels were decreased. These results
suggest that the difference in GI between the two formulas
tested in the current study may have contributed to the effects
on insulin resistance and fasting glucose, although only one
meal and one snack/day were replaced by a low-GI formula.
Also the intake of isomaltulose may have lowered the
glycemic response to the lunch, although this was not studied.
In a study in healthy men consuming an isomaltulose-
containing liquid formula during breakfast, lower levels of
glucose and insulin were found after a standard lunch as
compared with consumption of a high-GI formula during
breakfast [33]. The different types of proteins may also have
contributed to the effect on fasting glucose and insulin
resistance. In a diabetes rat model (Goto Kakazaki), it was
found that feeding for 2 weeks with a combination of whey
and soy protein significantly improved insulin sensitivity,
fasting glucose concentrations and fructosamine levels as
compared with feeding with casein [28]. These effects may be
explained by the higher aspartate content of the soy/whey
protein combination as compared with casein and thereby an
improvement in mitochondrial energy metabolism via better
functioning of the aspartate/malate shuttle [34].
Some other studies also determined the effect of a diabetes-
specific liquid formula as (part of) breakfast in patients with
impaired glucose tolerance and/or diabetes [35,36]. In over-
weight Chinese type 2 diabetes patients, a liquid diabetes-
specific formula was used to replace breakfast food items such
as milk, soymilk, rice soup or congee at the morning meal [36].
Postprandial glucose levels were not determined, but fasting
glucose, insulin and HbA1c levels were improved in the
intervention group after 24 weeks. However, the intervention
not only consisted of a diabetes-specific formula, but also
diabetes education with frequent blood glucose monitoring,
nutritional counseling, and weekly progress updates with study
staff compared to diabetes education only in the reference
group. Therefore, it is not possible to determine the contribution
of the diabetes-specific formula to the observed effects. In
another study, an isomaltulose-based liquid formula was used
as part of breakfast during 5 months in subjects with impaired
glucose tolerance or type 2 diabetes [35]. At the end of the study,
HbA1c and serum 8-hydroxydeoxyguanosine levels were
significantly decreased compared to those at baseline. Unfor-
tunately, no control group was used, which makes it difficult to
interpret the results. In the current study of 4 weeks,
fructosamine levels were not significantly different between
groups. It would be interesting to study the effects of longer-
term use of the diabetes-specific formula on HbA1c. Not only
fasting glucose levels, but also the postprandial glucose
concentrations play a major role in overall glycemic control
(HbA1c) [9,37].
Both formulas used in the present study had the same
amount of calories. Nevertheless, after 4 weeks, the change in
body weight was significantly different between the groups,
being increased in the control group and slightly decreased inthe diabetes-specific group. The isomaltulose in the diabetes
formula may have contributed to this effect. In a study in 10
overweight persons, ingestion of isomaltulose as compared to
sucrose was of benefit in stimulating postprandial fat
oxidation [38], which implies a supportive effect on body
weight control in obesity. A shift towards a greater postpran-
dial fat use may also attenuate fat accumulation in non-
adipose tissues leading to reduced insulin resistance. This is
line with the observed effects in the current study on insulin
resistance. In a rat study with an isomaltulose-based formula
improved insulin sensitivity and reduced visceral fat accumu-
lation were found as well [39]. Caloric intake was not recorded
in this study, so it is not known whether a different caloric
intake accounted for the differences in body weight.
In conclusion, the results of this study show that the
superior postprandial glucose control after intake of a
diabetes-specific formula was maintained after 4 weeks use
by type 2 diabetes patients, compared to a standard formula.
Furthermore, 4 weeks use of a standard liquid formula had
negative effects on body weight, fasting glucose and HOMAIR,
although the latter two effects may be confounded by the
observed effect on body weight. These results show that the
use of a diabetes-specific formula as meal replacement has a
clear added value with respect to postprandial glucose control
compared to a standard, fiber-containing formula in people
with type 2 diabetes and may contribute to improved glycemic
control (HbA1c) in the longer term. A longer term study of at
least 12 weeks would be necessary to show this.
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